article thumbnail

Research predicts 2029 small molecule oncology market leaders

European Pharmaceutical Review

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. billion and a market share of 17 percent by 2029, GlobalData predicted. percent by 2029.

article thumbnail

Our abysmal health care system

World of DTC Marketing

The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.

Insurance 263
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Artificial Intelligence and Life Expectancy: How AI Will Contribute to Improving Human Health.

MaBiCo

Personalized Medicine Thanks to AI, we will create simulations of the human body at the molecular, cellular and organ levels, allowing treatments to be personalized for each patient. This will lead to treatments that are more effective and safer, as the specificities of each patient will be taken into account.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143
article thumbnail

EGFR inhibitor could provide major advance in lung cancer

European Pharmaceutical Review

Small molecule treatment TAGRISSO ® (osimertinib) demonstrated a “statistically significant and highly clinically meaningful improvement” in progression-free survival (PFS) for Stage III lung cancer patients, AstraZeneca has confirmed. This was established from positive high-level results seen in the LAURA Phase III trial.

article thumbnail

Verona scores FDA approval for Ohtuvaye as COPD maintenance therapy

Pharmaceutical Technology

Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.

FDA 52
article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

The construction projects will be finalised from the end of 2025 through to 2029. This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide”, Wulff declared in the original annoucement.